Elicio Therapeutics Achieves Phase 2 Signal in ELI-002 7P After Missing Primary DFS Endpoint

A missed primary endpoint in Elicio Therapeutics' Phase 2 AMPLIFY-7P study has not closed the development path for ELI-002 7P in adjuvant pancreatic ductal adenocarcinoma, it has narrowed it, with implications for how manufacturers and CMOs position capacity for complex mKRAS-targeting immunotherapy platforms.

The randomized study did not meet its pre-specified primary endpoint of disease-free survival (DFS) in the intent-to-treat population. Post-hoc analysis, however, identified a meaningful DFS signal in the R0 completely resected subgroup (HR 0.65, p=0.048; median DFS 23.8 months vs. 12.8 months for observation; n=121). That subgroup represented approximately 84% of enrolled patients, a proportion large enough to anchor a viable Phase 3 design. A key confound in the ITT analysis was an imbalance in R1 resection status, a known adverse prognostic factor, with 19% of the ELI-002 7P arm classified R1 versus 10% in the observation arm.

The biological rationale remains intact. Mutant KRAS-specific T cell responses correlated strongly with improved DFS (HR 0.22, p<0.0001, n=90), supporting the mechanism of action and providing a potential pharmacodynamic marker for future trial stratification. The favorable safety and tolerability profile observed across AMPLIFY-7P supports the feasibility of extended dosing regimens and combination approaches in Phase 3, both of which carry direct consequences for drug substance batch scheduling and release testing timelines.

For QA directors and supply chain leads tracking oncology biologics pipelines, the refined Phase 3 strategy, centered on a defined R0 population with additional dosing cycles, signals increased per-patient drug product demand relative to the Phase 2 protocol. ELI-002 7P's amphiphilic lipid-conjugated peptide platform requires specialized manufacturing processes; any scale-up toward a registrational trial will demand early engagement on process validation under 21 CFR Part 211 and ICH Q10 quality system frameworks. Currently, no approved therapies exist following locoregional treatment in this setting, which elevates the regulatory and commercial stakes for getting manufacturing readiness right ahead of a Phase 3 IND amendment.

Elicio has disclosed it is evaluating strategic financing and partnering opportunities to support further clinical development, suggesting that CDMO selection and tech transfer timelines will be active considerations in the near term.

The Phase 3 protocol design, including final patient selection criteria and dosing schedule, will serve as the critical checkpoint against which manufacturing capacity commitments and process validation milestones should be benchmarked.

Source: Elicio Therapeutics via GlobeNewswire, June 15, 2026. Conference call hosted June 15, 2026, at 8:30 AM ET.